Health Care & Life Sciences » Biotechnology | Heat Biologics Inc.

Heat Biologics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
21,864.20
14,413.30
11,630.00
7,842.70
9,763.10
27,724.30
Total Accounts Receivable
24.90
-
-
82.30
14.80
28.50
Other Current Assets
1,066.60
863.20
869.00
338.00
1,967.30
961.30
Total Current Assets
22,955.70
15,276.50
12,499.00
8,263.00
11,745.20
28,714.10
Net Property, Plant & Equipment
53.80
445.50
446.00
359.60
286.90
643.10
Total Investments and Advances
1.30
101.10
101.00
101.20
2.30
-
Long-Term Note Receivable
-
48.60
58.00
103.00
-
-
Intangible Assets
-
-
-
-
8,055.30
8,055.30
Other Assets
9.30
44.40
114.00
69.80
99.80
351.20
Total Assets
23,020.10
15,916.20
13,218.00
8,896.60
20,189.50
60,682.90
ST Debt & Current Portion LT Debt
-
397.50
3,134.00
-
-
Accounts Payable
651.90
-
-
-
1,033.70
Other Current Liabilities
528.40
2,173.40
3,827.00
1,595.20
9,302.80
Total Current Liabilities
1,180.30
2,570.90
6,961.00
1,595.20
10,336.50
Long-Term Debt
-
2,314.10
3,612.00
-
-
Deferred Taxes
-
-
-
-
1,302.20
Other Liabilities
122.60
-
150.00
461.40
2,769.90
Total Liabilities
1,302.90
4,885.00
10,723.00
2,056.70
14,408.60
Common Equity (Total)
21,991.90
11,760.40
4,051.00
8,796.60
7,370.80
Total Shareholders' Equity
21,991.90
11,760.40
4,051.00
8,796.60
7,370.80
Total Equity
21,717.10
11,031.20
2,495.00
6,839.90
5,780.90
Liabilities & Shareholders' Equity
23,020.10
15,916.20
13,218.00
8,896.60
20,189.50
Accumulated Minority Interest
274.80
729.20
1,556.00
1,956.60
1,589.80

About Heat Biologics

View Profile
Address
801 Capitola Drive
Durham North Carolina 27713
United States
Employees -
Website http://www.heatbio.com
Updated 07/08/2019
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.